News & Views

Read the latest from Baszucki Group and its partners.

Magnus Medical Receives FDA Clearance for the SAINT Neuromodulation System for Non-Invasive, Individualized and Precise Treatment of Severe Depression

September 6, 2022 — The FDA has approved the SAINT Neuromodulation System for the treatment of major depressive disorder in adults who have not seen improvement using antidepressant medications. The Baszuckis are proud to have partnered with Nolan Williams and Magnus Medical to make this timely and personalized treatment accessible to patients with debilitating conditions.

Read More

Baszucki Brain Research Fund and Milken Institute launch Metabolic Mind Award Program for advancements in metabolic psychiatry

August 17, 2022 — The Baszucki Brain Research Fund and the Milken Institute’s Center for Strategic Philanthropy today announced the launch of the Metabolic Mind Award Program, recognizing champions working at the intersection of metabolism and mental health in the emerging field of metabolic psychiatry. This year’s award focus will be on Ketogenic Metabolic Therapy for mental health.

Read More

A Startup Philanthropy Targeting Serious Mental Illness Ramps Up

July 21, 2022 — The Baszuckis are showing how philanthropy, even one organization, can potentially make a big impact on an underfunded field of research. But they can’t solve this on their own — by getting this new research rolling, their most significant role could be producing promising results that attract new funders to the space.

Read More

Baszucki Brain Research Fund Backs First Clinical Pilot Trials of Ketogenic Metabolic Interventions for Mental Health Conditions in Nearly 60 Years

July 18, 2022 — The Baszucki Brain Research Fund is pleased to announce that five science teams around the globe have received funding to study ketogenic metabolic interventions for bipolar disorder, schizophrenia and major depressive disorder.

Read More